JNJ AI Stock Analysis – Buy, Hold, or Avoid?
Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) is a fundamentally robust, diversified healthcare leader trading near all-time highs with strong technical momentum but a full valuation and moderate risk from litigation and patent cliffs. While the long-term outlook remains positive due to innovation and defensive business strength, near-term upside is limited unless a breakout or major catalyst emerges. Investors should hold or accumulate on dips, with a focus on long-term stability rather than immediate gains.
Fundamentals
Johnson & Johnson (JNJ) continues to demonstrate exceptional financial stability and robust earnings power, underpinned by consistent revenue and earnings growth. Profitability remains a core strength, with high margins and effective execution visible in a steady beat pattern on earnings. While the stock appears fully valued at present, JNJ’s defensive business model and history of reliable performance make it a compelling long-term holding, though near-term returns may be modest.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
9.08% YoY
Q4 2025
Net Income
49.11% YoY
Q4 2025
Net Margin
Q4 2025
Growth Metrics
Revenue Growth YoY
Latest Quarter: Q4 2025
Net Income Growth YoY
Latest Quarter: Q4 2025
Revenue Per Share Growth YoY
Latest Quarter: Q4 2025
EPS Growth YoY
Latest Quarter: Q4 2025
Book Value Per Share Growth YoY
Latest Quarter: Q4 2025
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 24.6B | 24.0B | 23.7B | 21.9B | 22.5B | 22.5B | 22.4B | 21.4B |
| Revenue Growth YoY | +9.08% | +6.77% | +5.77% | +2.39% | +5.26% | +5.25% | +4.31% | +2.34% |
| Net Income | 5.1B | 5.2B | 5.5B | 11.0B | 3.4B | 2.7B | 4.7B | 3.3B |
| Net Income Growth YoY | +49.11% | +91.24% | +18.16% | +237.91% | -15.26% | -89.65% | -8.90% | +4886.76% |
| EPS | $2.10 | $2.14 | $2.29 | $4.57 | $1.43 | $1.12 | $1.95 | $1.35 |
| EPS Growth YoY | +46.85% | +91.07% | +17.44% | +238.52% | -14.88% | -89.15% | -1.52% | +4600.00% |
Profitability Metrics
Gross Margin
TTM
Operating Margin
TTM
Net Margin
TTM
Return on Equity
TTM
Return on Assets
TTM
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.37% | 69.56% | 67.87% | 66.40% | 68.35% | 69.01% | 69.40% | 69.55% |
| Operating Margin | 21.95% | 29.58% | 28.68% | 28.77% | 17.06% | 23.49% | 29.66% | 29.34% |
| Net Margin | 20.83% | 21.47% | 23.32% | 50.24% | 15.24% | 11.99% | 20.88% | 15.22% |
| Return on Equity (ROE) | 6.27% | 6.50% | 7.06% | 14.08% | 4.80% | 3.84% | 6.55% | 4.65% |
| Return on Assets (ROA) | 5.11% | 5.36% | 5.80% | 9.78% | 3.49% | 2.87% | 4.83% | 3.22% |
Technical Analysis
JNJ is currently in a strong uptrend with price trading well above key moving averages, supported by a golden cross and a robust ADX that signals a strong trend. The stock is approaching its 52-week high, indicating bullish momentum, though RSI remains neutral, showing no immediate overbought condition. This technical setup suggests sustained upward price action with healthy momentum.
No extreme reading
Price in uptrend
Strong trend active
50 above 200 - bullish
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
Johnson & Johnson (JNJ) continues to demonstrate exceptional financial stability and robust earnings power, underpinned by consistent revenue and earnings growth. Profitability remains a core strength, with high margins and effective execution visible in a steady beat pattern on earnings. While the stock appears fully valued at present, JNJ’s defensive business model and history of reliable performance make it a compelling long-term holding, though near-term returns may be modest.
Latest Earnings
Q4 2025 Earnings (Dec 28, 2025)
Earnings Per Share (EPS)
Actual
$2.46
Estimated
$2.46
Surprise
$0.00
Surprise %
0.00%
Revenue
Actual
$24.56B
Estimated
$24.15B
Surprise
+$416.01M
Surprise %
+1.72%
Historical Earnings
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $2.46 | $2.80 | $2.77 | $2.77 | $2.04 | $2.42 | $2.82 | $2.71 |
| EPS (Estimated) | $2.46 | $2.76 | $2.68 | $2.58 | $1.99 | $2.21 | $2.71 | $2.64 |
| EPS Surprise | +$0.00 | +$0.04 | +$0.09 | +$0.19 | +$0.05 | +$0.21 | +$0.11 | +$0.07 |
| % Diff | +0.0% | +1.4% | +3.4% | +7.4% | +2.5% | +9.5% | +4.1% | +2.7% |
| Revenue | ||||||||
| Revenue (Actual) | $24.56B | $23.99B | $23.74B | $21.89B | $22.52B | $22.47B | $22.45B | $21.38B |
| Revenue (Estimated) | $24.15B | $23.76B | $22.85B | $21.56B | $22.43B | $22.17B | $22.33B | $21.4B |
| Revenue Surprise | +$416.01M | +$237.64M | +$889.03M | +$334.38M | +$88.78M | +$299.19M | +$116.62M | -$17.95M |
| % Diff | +1.7% | +1.0% | +3.9% | +1.6% | +0.4% | +1.3% | +0.5% | -0.1% |
Valuation
Johnson & Johnson (JNJ) currently exhibits a solid fundamental and financial profile with stable earnings growth and strong margins. The valuation metrics suggest the stock is trading slightly below or near sector averages, supported by a robust pipeline and diversified healthcare exposure, which underpin its moderate premium valuation. Analyst sentiment is cautiously optimistic, indicating potential upside in the medium term despite certain headwinds like litigation and generic competition.
Valuation Metrics
Price to Earnings
TTM
Price to Sales
TTM
Price to Book
TTM
Enterprise Value to EBITDA
TTM
Enterprise Value to Revenue
TTM
| Q4 2025 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Price to Earnings | 24.56 | 24.63 | 21.40 | 16.68 | 9.07 | 25.14 | 36.20 | 18.80 |
| Price to Sales | 20.46 | 20.52 | 18.38 | 15.56 | 18.22 | 15.32 | 17.36 | 15.70 |
| Price to Book | 0.00 | 6.18 | 5.56 | 4.71 | 5.11 | 4.83 | 5.56 | 4.93 |
| Enterprise Value to EBITDA | 0.00 | 85.68 | 50.46 | 45.95 | 26.44 | 60.39 | 75.49 | 47.32 |
| Enterprise Value to Revenue | 0.00 | 21.67 | 19.53 | 16.92 | 18.85 | 15.88 | 18.06 | 16.44 |
Sentiment & Analyst Ratings
The sentiment around Johnson & Johnson (JNJ) is cautiously optimistic with a Moderate Buy consensus held by most analysts. While the company benefits from strong financials, a diverse healthcare portfolio, and promising clinical developments, cautious investor sentiment is influenced by ongoing litigation and patent expiration risks. Retail investors similarly show supportive but measured confidence amid the stock's recent strong performance near 52-week highs.
Analyst Recommendations
Risk Assessment
Johnson & Johnson maintains a solid financial profile with stable liquidity and moderate leverage, supported by strong operational sales growth and robust pipeline prospects. The company faces ongoing risks from patent expirations, litigation, and regulatory challenges, but its diversified business model and strategic initiatives position it well for sustainable growth. Analyst sentiment is generally positive, reinforcing confidence in JNJ's mid-term outlook despite valuation and litigation uncertainties.
Liquidity & Solvency
Current Ratio
Latest Quarter: Q4 2025
Quick Ratio
Latest Quarter: Q4 2025
Debt-to-Equity
Latest Quarter: Q4 2025
Debt-to-Assets
Latest Quarter: Q4 2025
| Q4 2025 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Liquidity Metrics | ||||||||
| Current Ratio | 0.00 | 1.03 | 1.07 | 1.01 | 1.26 | 1.11 | 1.03 | 1.07 |
| Quick Ratio | 0.77 | 0.77 | 0.80 | 0.76 | 1.03 | 0.86 | 0.79 | 0.85 |
| Solvency Metrics | ||||||||
| Debt-to-Equity | 0.00 | 0.59 | 0.58 | 0.65 | 0.67 | 0.51 | 0.51 | 0.58 |
| Debt-to-Assets | 0.00 | 0.24 | 0.24 | 0.26 | 0.27 | 0.20 | 0.20 | 0.23 |
Liquidity Assessment
Current Ratio: 1.03(Adequate)
Quick Ratio: 0.77(Weak)
The company has relatively weak liquidity and may face challenges meeting short-term obligations.
Solvency Assessment
Debt-to-Equity: 0.59(Moderate)
Debt-to-Assets: 0.24(Low)
The company maintains a balanced capital structure with manageable debt levels.
Frequently Asked Questions about JNJ
AI Answers: Common Questions About JNJ
Get AI-powered answers to the questions investors ask most about Johnson & Johnson
JNJ is trading at $246.75 with a P/E of 22.35, slightly below the sector median but above some peers, and near its 52-week high of $251.71. While the fundamentals are strong and technical momentum is positive, the stock appears fairly valued, so it is not a screaming buy at current levels—wait for a breakout or pullback for a better entry.
There is no compelling reason to sell JNJ now unless you are highly risk-averse to litigation outcomes or need to rebalance; fundamentals remain robust, technicals are bullish, and sentiment is stable. Consider trimming only if the stock fails to break out above resistance or if litigation risks escalate materially.
The biggest risks are ongoing talc litigation (with debt-to-equity at 0.58 and debt-to-assets at 24% providing some cushion), patent cliffs leading to biosimilar competition, and regulatory pressures on drug pricing. While liquidity is stable (current ratio just above 1), these risks could compress margins or valuation if realized.
Technically, the next upside target is $260 if JNJ breaks above the $251.71 resistance; support lies at $240 and $225 (50 SMA). Analyst price targets have been raised recently, generally supporting modest upside from current levels, but a sustained move above $252 is needed for a new leg higher.
JNJ is fairly valued: its P/E of 22.35 is moderate for healthcare, EV/EBITDA is on the higher side versus peers, and price-to-sales is premium, reflecting quality and stability. The current valuation is justified by strong margins and pipeline, but leaves limited room for multiple expansion unless growth accelerates.
JNJ is fundamentally strong, with 2025 gross margin at 72.8%, net margin at 28.5%, and ROE above 20%. Revenue grew 6.1% YoY to $94.2B, and net income surged 90.7% YoY, with a strong, diversified business model and reliable cash generation.
Technical analysis is bullish: price is above all major moving averages, a golden cross is in place, ADX is strong at 38.8, and RSI is at 67.46 (not yet overbought). Key resistance is at $251.71; a breakout could target $260, while support is at $240 and $225.
Key catalysts include upcoming earnings reports, potential breakout above $251.71, positive clinical trial results (e.g., pasritamig, nipocalimab), FDA approvals, and resolution or abatement of litigation risks. Watch for macro healthcare policy changes and major M&A activity as additional drivers.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.